Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
View & Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 463.45A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 7
Average PDX Generation Time (days +/- SEM) 62 ± 4
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 463.45A
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
463.45A MSH2 -0.85894 1.10272 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A TP53 -0.89322 1.07682 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A FANCA -0.930846 1.0491 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A FANCA -0.775385 1.16847 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A CDH1 -0.892144 1.07763 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A SUFU -0.765902 1.17617 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A PTEN -0.765902 1.17617 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A IGF2R -1.55146 0.682329 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A XPO1 -0.920105 1.05694 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A SETD2 -0.819225 1.13349 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A RAF1 -0.881977 1.08525 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A FANCD2 -0.881977 1.08525 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A MET 0.689479 3.2254 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A GNAS 0.846908 3.59728 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A GNAS 1.0795 4.22661 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A SPOP 1.16347 4.47991 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A FOXA1 0.505725 2.83967 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A NCOR2 0.65559 3.15052 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A STAB2 0.706515 3.26371 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A MYC 1.22924 4.68887 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A CHD7 1.64054 6.23565 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A KMT2C 0.689479 3.2254 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A EZH2 0.689479 3.2254 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.45A BRAF 0.689479 3.2254 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 463.45A
Sample Site Tumour under diaphragm
Sample source Autopsy
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel

Patient Information

Patient Number 455/463
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 7.8
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 463.45A
Patient Age (binned in 5 year age groups) 55-59
This heatmap displays the mutations of curated sequence variants.
Download The Mut plot is not shown
PDX ID Gene Symbol Depth ALT_FREQ Consequence Exon GnomAD_AF CADD_PHRED Clinvar_clnsig Platform Experiments Name Reference Library Type Instrument Type
463.45A GPR124 232 1.0 missense_variant '8/19 2.04E-05 26.5 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.45A TP53 127 1.0 stop_gained '7/11 . 37 Pathogenic Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.45A NCOR1 366 0.49 missense_variant '28/46 0.0007429 33 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.45A ZFHX3 110 0.47 inframe_insertion '10/10 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.45A SPTA1 283 0.31 splice_acceptor_variant . . 34 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500